Navigation Links
Replacement Bulb: USH-102DH

ProductsReplacement Bulb: USH-102DH
Company Bulb Direct, Inc.
Item Replacement Bulb: USH-102DH
Features 
Description Bulb Direct has been selling replacement bulbs on the Internet since 1996, and we are extremely proud of our 100% satisfaction guarantee. Check out our catalog of replacement bulbs and see our discount light bulbs specials.

Check our web site for additional brands and prices.
Info Bulb Direct, Inc.
Customer Service: (800) 772-5267
Web site: http://www.bulbdirect.com/

Related medicine products :

1. Replacement Burr/Chuck
2. Replacement Burr
3. Replacement Burr Set
4. Replacement Needle Tip
5. Replacement Gouge Tip
6. Replacement Handle
7. Snare Wire Replacements for E3525 3/package
8. Healos Bone Graft Replacement
9. Verte-Span Vertebral Body Replacement
10. Vertebral Body Replacement (VBR)
11. Perfecta PDA Calcar Replacement Stems
The ImmunoWELL VZV IgG Test is an ELISA method for the qualitative detection of IgG to Varicella Zoster virus (VZV). Test results are used as,an aid to determine immune status or infection. Immune st
...tBlot G Tests are qualitative enzyme immunoassays ...rgdorferi antibodies (IgG or IgM, respectively) in...ests should be supplemented with a standardized we...an be used to support a clinical diagnosis of B. b...
The ImmunoWELL TPO IgG Quantitative Test is a quantitative enzyme immunoassay (EIA) for screening and detection of autoantibodies against human thyroid peroxidase (microsome) in serum and is used as
The ImmunoDOT Autoimmunity Screening Panel 6 is an enzyme immunoassay (EIA) test for screening and detection of autoantibodies against various specific nuclear antigens (SS-A, SS-B, RNP/Sm, Sm, Jo-1,
Medicine Products:
(Date:12/2/2008)...h differences between groups of immigrants in Oslo...so great. The differences are seen for risk factor...rt from the Norwegian Institute of Public Health. ... with each other and the ethnic Norwegian populati... health care better. , The five immigrant group...
(Date:12/2/2008)...ewswire/ -- Smile Reminder, the nation,s leading,...led the latest in industry,technology today at Ja...tool,for capturing and distributing video testimo...testimonials onto popular platforms such as YouTub...provides doctors with an effective,business strat...
(Date:12/2/2008)...sday, December 2, 2008 at 3 pm CST)--Radiology and...rsity of South Carolina in Charleston, S.C., today...om exposure to radiation during computed tomograph...nd that new estimates are several times lower than...rchers presented their findings at the annual mee...
(Date:12/2/2008)...s establish special bonds between partners. Oftent...rships, and ultimately, the start of families. , ...o much emotional weight on their relationship. As ...self-worth solely based on the outcomes of their r...erm as relationship-contingent self-esteem (RCSE),...
Breaking Medicine News(10 mins):Health News:Large health differences between population groups in Norway 2Health News:Large health differences between population groups in Norway 3Health News:Large health differences between population groups in Norway 4Health News:Doctors Go Viral: vSling Video Testimonial Tool Offers Doctors Access to New Channels for Acquiring Patients 2Health News:Doctors Go Viral: vSling Video Testimonial Tool Offers Doctors Access to New Channels for Acquiring Patients 3Health News:Radiological Society of North America research: Cancer risk from cardiac CT overstated 2Health News:Too much commitment may be unhealthy for relationships, UH psychology professor says 2
...Netherlands the effects of multiple sclerosis (MS)...ger portions of the brain, which seemingly appear ... Vrenken, Ph.D., from the Multiple Sclerosis Cente...msterdam, who have published their findings that i...
...ry medicine cabinet, may help in easing out prosta...yo Clinic.// Aspirin is known to help in the prev...strokes and several types of cancer along with hea...t may help solve some of the urinary problem thoug...
...te of the University of Sao Paulo Medical School i... advice was the key to// getting the best care in ...ndings of the study to be published in the Septemb...can College of Cardiology showed that patients ass...
...laming GOP lawmakers for not seeking lower prices ...n launched by the// Association of Trial Lawyers o...e lawmakers for blocking provisions that would hav... drug companies for the best prescription cost has...
Other Medicine News:Health News:Damage Due to MS Might Extend Into Larger Portions Of The Normal Brain 2Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 2Health News:Patient’s Individual Cardiologist Best Judge For Deciding Appropriate Treatment In Chronic Coronary Artery Diseas 3Health News:Ad Campaign Targeting Republicans On Medicare Prescription Drug Program 2
(Date:12/2/2008)...CHICAGO, Dec. 3 Breast-... detection of cancers not found on mammograms or b...oday at the annual meeting of,the Radiological So...identify the most difficult to detect breast cance...achel F. Brem, M.D., professor of,radiology and d...
(Date:12/2/2008)...SKOKIE, Ill., Dec. 2 Horizon Thera... company, today announced that two pivotal,Phase ...ct candidate, HZT-501,met all primary endpoints....tion product containing ibuprofen and famotidine, ...n in the incidence of non-steroidal,anti-inflamma...
(Date:12/1/2008)...ROCKVILLE, Md., Dec. 1 V...s publication in The Lancet , one of the world,s ...ls of its novel circadian regulator, experimental ...y Rajaratnam et al(1) is entitled "Melatonin agoni...ter sleep-time shift: two randomised controlled mu...
(Date:12/1/2008)...Baby Girl with Hypophosphatasia Treated With ENB-0... in Winnipeg , , MONTREAL, Dec. 1 /PRNewswi... company focused on developing novel therapeutics ...he first infant patient in its clinical program fo...ing Enzyme Replacement Therapy (ERT) with ENB-0040...
Breaking Medicine Technology:New Breast Imaging Technology Targets Hard-to-Detect Cancers 2New Breast Imaging Technology Targets Hard-to-Detect Cancers 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Acupuncture reduces pain and dysfunction in head and neck cancer patients after neck dissection 20751 1Acupuncture reduces pain and dysfunction in head and neck cancer patients after neck dissection 20751 2VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 1VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 2VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 3VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 4VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 5VELCADE 28R 29 28Bortezomib 29 for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Mult 2254 6Patients with Pancreatic Cancer Can Benefit From Avastin 28R 29 Plus Tarceva 28R 29 2251 1Patients with Pancreatic Cancer Can Benefit From Avastin 28R 29 Plus Tarceva 28R 29 2251 2Patients with Pancreatic Cancer Can Benefit From Avastin 28R 29 Plus Tarceva 28R 29 2251 3Chemo May Limit Fertility in Breast Cancer Survivors 20748 1Chemo May Limit Fertility in Breast Cancer Survivors 20748 2
...ontinue Phase II Profiling,in Diabetic Patients ,...ne 2007-Speedel,(SWX: SPPN) today announced that i... development of its family of renin inhibitors wit...f-concept clinical,trial with SPP635 for the treat...lts, the company is to continue developing SPP635 ...
...(BUSINESS WIRE)--Jun 28, 2007,- Progenics Pharmace...cals, a division of Wyeth (NYSE: WYE), today annou...l extension study of,subcutaneous methylnaltrexone...(OIC) in patients with advanced illness. The resul...nal Association of,Supportive Care in Cancer (MASC...
Other Medicine Technology:Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 2Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 3Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 4Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 5Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 6Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 7Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension 8Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 2Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 3Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 4Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 5Progenics and Wyeth Announce Positive Results from Three-Month,Clinical-Extension Study of Subcutaneous Methylnaltrexone for the,Treatment of Opioid-Induced Constipation in Patients with Advanced,Illness 6